전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved50 programs
AntibodyLimited DatastaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, dosage RP2D-1, KF-0210 (dosage RP2D-1) + Atezolizumab)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#ColorectalCancer+1
Trials 1Status Active
AntibodyLimited DatastaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, dosage RP2D-2, KF-0210 (dosage RP2D-2) + Atezolizumab)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#ColorectalCancer+1
Trials 1Status Active
AntibodyLimited DatastaleAustralasian Gastro-Intestinal …Phase 3

Mitomycin C; Capecitabine; Bevacizumab (Mitomycin C; Capecitabine; Bevacizumab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase3#monoclonal-antibody#Australasian
Trials 1Status Active
CGTLimited DatastaleNovartis PharmaceuticalsPhase 3

Previously treated CAR-T patients (Previously treated CAR-T patients)

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program · Long Term Safety of Patients Receiving C

#LongTermSafetyofPatientsReceivin#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastaleRegeneron PharmaceuticalsPhase 2

REGN17372+Linvoseltamab (REGN17372+Linvoseltamab)

Relapsed Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedRefractoryMultipleMyelom+1
Trials 1Status Recruiting
CGTLimited DatastaleBellicum Pharmaceuticals, Inc.Phase 1

TROP2-CAR-NK Cells (TROP2-CAR-NK Cells)

Colorectal Cancer; Minimal Residual Disease · TROP2

#TROP2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleBeijing Biostar Pharmaceuticals…Phase 2

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Non-small Cell Lung Cancer Patients with Brain Metastases · Non-small Cell Lung Cancer Patients with

#Non-smallCellLungCancerPatientsw#Antibody#Phase2#monoclonal-antibody#Beijing
Trials 1Status Recruiting
CGTLimited DatastaleBellicum PharmaceuticalsPhase 1

iC9.GD2.CAR.IL-15 T Infusion (iC9.GD2.CAR.IL-15 T Infusion)

Lung Cancer; Small Cell Lung Carcinoma · GD2

#GD2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleSpectrum Pharmaceuticals, IncPhase 2

indium-111-ibritumomab tiuxetan (indium-111-ibritumomab tiuxetan)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#monoclonal-antibody#Spectrum
Trials 1Status Discontinued
AntibodyLimited DatastaleKiniksa Pharmaceuticals Interna…Phase 3

mavrilimumab (mavrilimumab)

COVID · COVID

#COVID#Antibody#Phase3#monoclonal-antibody#Kiniksa
Trials 1Status Active

3 / 3 pages

← PreviousNext →